Researchers tested whether certain patients with HER2-positive breast cancer may eventually be eligible for non-surgical management.
Patients with follicular lymphoma or diffuse large B-cell lymphoma with a low peripheral blood natural killer cell count at baseline had shorter time to progression.
Researchers have found several characteristics identified on PET/CT that may help to predict early clinical failure of untreated follicular lymphoma.
Researchers looked at the use and effects of 5α-reductase inhibitors to treat benign prostatic hyperplasia on prostate cancer outcomes.
Final results of LATITUDE confirm the benefit of abiraterone acetate plus prednisone along with ADT in high-risk metastatic castration-sensitive prostate cancer.
The percentage of patients with cancer eligible to receive immune checkpoint inhibitors has increased in recent years, but how many patients are actually responding?
The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer.
Researchers tested the addition of the T cell–boosting decitabine to anti–PD-1 therapy with camrelizumab among patients with relapsed or refractory classic Hodgkin lymphoma.
In this patient-reported outcomes analysis of the COMBI-AD study, researchers looked at the health-related quality of life in those with resected stage III melanoma with BRAF mutations.
The MYD88 driver mutation was detected in the cerebrospinal fluid of a majority of patients with CNS lymphoma, indicating its potential utility as a diagnostic and monitoring tool.